 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Bioventure SLS Bio, which is seeking to be listed on the KOSDAQ, announced on the 26th that it conducted demand forecasts for institutional investors from the 18th to the 22nd and confirmed the public offering price at KRW 7,000.
According to Hana Securities, which organizes the listing of SLS Bio, a total of 640 institutions from home and abroad participated in the demand forecast, recording a competition ratio of 235.14 to 1.
SLS Bio has a total of 770,000 shares, 100% of which are new shares. The total amount of public offering is KRW 5.39 billion based on the confirmed public offering price. The fund will focus on research and development and production facilities for technological advancement. Its strategy is to secure competitive advantage by building the latest facilities · equipment, adding test items, and developing specialized in vitro diagnostic devices, and expand its global business in major countries such as the United States, Europe and Japan.
Meanwhile, general investor subscription of SLS Bio will be held on October 10 and 11, and will be transferred to the KOSDAQ market in October. The holding company for the listing is Hana Securities.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
